Atsuko Furuta

Dr. Atsuko Furuta

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2023 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
EBEdward Barroga
Edward Barroga
GMGlafera Janet Matanguihan
Glafera Janet Matanguihan
AFAtsuko Furuta
Atsuko Furuta
MAMakiko Makiko Arima
Makiko Makiko Arima
STShizuma Tsuchiya
Shizuma Tsuchiya
MIMiki Izumi
Miki Izumi
Barroga E, et al. J Korean Med Sci. 2023 Aug;38(37):e291. https://doi.org/10.3346/jkms.2023.38.e291

12 May 2021 in Medicines
Verified
Journal Article
Open access
PDF file
TOTakayuki Okumo
Takayuki Okumo
AFAtsuko Furuta
Atsuko Furuta
TKTarou Kimura
Tarou Kimura
KYKanako Yusa
Kanako Yusa
Kazuhito AsanoKazuhito Asano
Kazuhito Asano
MASATAKA SUNAGAWAMASATAKA SUNAGAWA
MASATAKA SUNAGAWA
Background: Angiogenesis is well known to be an important event in the tissue remodeling observed in allergic diseases. Although there is much evidence that quercetin, one of the most abundant dietary flavonoids, exerts anti-allergic effects in both human and experimental animal models of allergic diseases, the action of quercetin on angiogenesis has not been defined. Therefore, in this study, we first examined the action of quercetin on the secretion of angiogenic factors from murine mast cells in vitro. We also examined the action of quercetin on angiogenic factor secretion in the murine allergic rhinitis model in vivo. Methods: Mast cells (1 × 105 cells/mL) sensitized with ovalbumin (OVA)-specific murine IgE were stimulated with 10.0 ng/mL OVA in the presence or the absence of quercetin for 24 h. The concentrations of angiogenic factors, vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), tumor necrosis factor-α, IL-6 and IL-8 in the supernatants were examined by ELISA. BALB/c male mice immunized with OVA were challenged intranasally with OVA every other day, starting seven days after the final immunization. These mice were then orally administered quercetin once a day for five days, starting seven days after the final immunization. Clinical symptoms were assessed by counting the number of sneezes and nasal rubbing behaviors during the 10 min period just after OVA nasal provocation. The angiogenic factor concentrations in the nasal lavage fluids obtained 6 h after nasal antigenic provocation were examined by ELISA. Results: Quercetin significantly inhibited the production of angiogenetic factors induced by IgE-dependent mechanisms at 5.0 µM or more. Oral administration of 25.0 mg/kg quercetin into the mice also suppressed the appearance of angiogenetic factors in nasal lavage fluids, along with the attenuation of nasal symptoms. Conclusions: These results strongly suggest that the inhibitory action of quercetin on angiogenic factor secretion may be implicated in the therapeutic action of quercetin on allergic diseases, especially allergic rhinitis.

21 April 2023 in Medicines
Verified
Journal Article
Open access
PDF file
AOAmane Oaki
Amane Oaki
AFAtsuko Furuta
Atsuko Furuta
Kazuhito AsanoKazuhito Asano
Kazuhito Asano
Background: Quercetin, a polyphenolic flavonoid found in various plants and foods, is known to have antioxidant, antiviral and anticancer effects. Although quercetin is well known to exert anti-inflammatory and anti-allergic effects, the precise mechanisms by which quercetin favorably modifies the clinical status of allergic diseases, such as allergic rhinitis (AR), remain unclear. The present study examined whether quercetin could modulate the production of the endogenous anti-inflammatory molecule, Clara cell 10-kD protein (CC10), in vitro and in vivo. Methods: Human nasal epithelial cells (1 × 105 cells/mL) were stimulated with 20 ng/mL of tumor necrosis factor-alpha (TNF) in the presence of quercetin for 24 h. CC10 levels in culture supernatants were examined by ELISA. Sprague Dawley rats were sensitised with toluene 2,4-diisocyanate (TDI) by intranasal instillation of 10% TDI in ethyl acetate at a volume of 5.0 μL once daily for five days. This sensitisation procedure was repeated after an interval of two days. The rats were treated with different dosages of quercetin once daily for five days starting on the 5th day following the second sensitization. Nasal allergy-like symptoms induced by the bilateral application of 5.0 μL of 10% TDI were assessed by counting sneezing and nasal-rubbing behaviours for 10 min immediately after the TDI nasal challenge. The levels of CC10 in nasal lavage fluids obtained 6 h after TDI nasal challenge were examined using ELISA. Results: The treatment of cells with low doses of quercetin (5.0 μM). The oral administration of quercetin (>25 mg/kg) for five days significantly increased the CC10 content in nasal lavage fluids and attenuated the nasal symptoms induced by the TDI nasal challenge. Conclusions: Quercetin inhibits AR development by increasing the ability of nasal epithelial cells to produce CC10.

1 January 2006 in Nihon Bika Gakkai Kaishi (Japanese Journal of Rhinology)
Verified
Journal Article
Open access
MSMiki Shino
Miki Shino
AFAtsuko Furuta
Atsuko Furuta
JUJun Uchida
Jun Uchida
EYEnatsu Yokomori
Enatsu Yokomori
ESEmiko Suzaki
Emiko Suzaki
HSHarumi Suzaki
Harumi Suzaki